Judgment of the Court of Justice in the case Salutas Pharma. The Combined Nomenclature in Annex I to Council Regulation (EEC) No 2658/87 of 23 July 1987 must be interpreted as meaning that a product, such as effervescent tablets with a calcium content of 500 mg per tablet that is used for the prevention and treatment of a calcium deficiency and to support a special therapy for the prevention and treatment of osteoporosis, and for which the maximum recommended daily dose for adults indicated on the label is 1 500 mg, falls within heading 3004 of that nomenclature.



Informatiesoort: Nieuws

Rubriek: Europees belastingrecht, Douane

H&I: Previews


Gerelateerde artikelen